The Department of Neurology, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands.
National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
Ann Neurol. 2019 May;85(5):777-781. doi: 10.1002/ana.25447. Epub 2019 Mar 25.
A reliable biomarker is needed for accurate and early differentiation between Parkinson disease and the various forms of atypical parkinsonism. We used a novel real-time quaking-induced conversion (RT-QuIC) assay to detect α-synuclein (α-syn) aggregates in cerebrospinal fluid (CSF) of 118 patients with parkinsonism of uncertain clinical etiology and 52 controls. Diagnostic accuracy to distinguish α-synucleinopathies from non-α-synucleinopathies and controls was 84% (sensitivity = 75%, specificity = 94%, area under the curve = 0.84, 95% confidence interval = 0.78-0.91, p < 0.0001, positive predictive value = 93%). CSF α-syn RT-QuIC could be a useful diagnostic tool to help clinicians differentiate α-synucleinopathies from other forms of parkinsonism when the clinical picture is uncertain. Ann Neurol 2019;85:777-781.
我们使用一种新型的实时液流变学诱导转换（RT-QuIC）检测方法，检测了 118 例临床病因不确定的帕金森病患者和 52 例对照者的脑脊液（CSF）中的α-突触核蛋白（α-syn）聚集物。该检测方法在区分α-突触核蛋白病与非α-突触核蛋白病和对照组方面的诊断准确性为 84%（敏感性=75%，特异性=94%，曲线下面积=0.84，95%置信区间=0.78-0.91，p<0.0001，阳性预测值=93%）。当临床表现不确定时，CSF α-syn RT-QuIC 可能成为一种有用的诊断工具，帮助临床医生区分α-突触核蛋白病与其他形式的帕金森病。
